Zobrazeno 1 - 10
of 714
pro vyhledávání: ''
Autor:
Ricardo Bruges, Pamela Salman, Ruben Dario Kowalyszyn, M. Li, Lucjan Wyrwicz, Valerie Poulart, Michalis V. Karamouzis, Arinilda Silva Campos Bragagnoli, Roberto Pazo-Cid, Marcelo Garrido, Yelena Y. Janjigian, Tomasz Skoczylas, Lin Shen, Mustapha Tehfe, Kensei Yamaguchi, Ming Lei, Michael Schenker, Thomas Zander, H. Xiao, Erika Hitre, Kynan Feeney, Markus Moehler, Kaoru Kondo, Kohei Shitara, Patricio Eduardo Yanez, Tianshu Liu, Dana Cullen, James M. Cleary, Jaffer A. Ajani
Publikováno v:
The Lancet. 398:27-40
First-line chemotherapy for advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma has a median overall survival (OS) of less than 1 year. We aimed to evaluate first-line
Autor:
Hanns-Ulrich Marschall
Publikováno v:
The Lancet. 394:810-812
Autor:
Sofia Tosounidou, Freya M Lodge, Colin D. Chue, Desley Neil, Elizabeth Curtis, William Bradlow, William E. Moody
Publikováno v:
The Lancet. 398:1913
Autor:
Bing Y. Suen, Vincent Wai-Sun Wong, Vivian W Y Lee, Heyson Chan, Grace Lai-Hung Wong, Siew C. Ng, Ka Man Kee, Justin C.Y. Wu, Yee-Kit Tse, Kim W.L. Au, Pui Kuan Cheong, Kelvin Long-Yan Lam, Moe H. Kyaw, Angeline Lo, Jessica Y.L. Ching, Francis K.L. Chan
Publikováno v:
The Lancet. 389:2375-2382
Summary Background Present guidelines are conflicting for patients at high risk of both cardiovascular and gastrointestinal events who continue to require non-steroidal anti-inflammatory drugs (NSAIDs). We hypothesised that a cyclooxygenase-2-selecti
Autor:
Hertzel C. Gerstein
Publikováno v:
The Lancet. 395:559-560
Autor:
Viktoria Werkström, Eugene R. Bleecker, Marek Lommatzsch, Magnus Aurivillius, Stephanie Sproule, Mitchell Goldman, Gary T Ferguson, Geoffrey Gilmartin, Ken Ohta, Stephanie Korn, Peter Barker, Parameswaran Nair, William W. Busse, J. Mark FitzGerald
Publikováno v:
The Lancet. 388:2128-2141
Summary Background Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor α monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils. We aimed to assess the efficacy and safety of benralizumab as a
Autor:
Douglas Adkins, Damien M. Cronier, Gary K. Schwartz, Gregory K. Pennock, Gaurav D. Shah, Ilaria Conti, Robert Ilaria, Meera Hameed, Ashwin Shahir, Anthony D. Elias, Matthew M. Cooney, Michael B. Livingston, Bartosz Chmielowski, Jan Cosaert, William D. Tap, Amy Qin, Robin L. Jones, Brian A. Van Tine, Mark Agulnik
Publikováno v:
The Lancet. 388:488-497
Summary Background Treatment with doxorubicin is a present standard of care for patients with metastatic soft-tissue sarcoma and median overall survival for those treated is 12–16 months, but few, if any, novel treatments or chemotherapy combinatio
Autor:
Julien Mazieres, Gérard Zalcman, Jean-Jacques Parienti, Bernard Milleron, Olivier Molinier, Marie-Paule Lebitasy, Frédéric Rivière, Chrystele Locher, Arnaud Scherpereel, Laurent Greillier, Valérie Gounant, Franck Morin, Romain Corre, Denis Moro-Sibilot, Clarisse Audigier-Valette, H. Janicot, Christian Creveuil, Jacques Margery, Radj Gervais, Isabelle Monnet, Quan Tran
Publikováno v:
The Lancet. 387:1405-1414
Summary Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis, linked to occupational asbestos exposure. Vascular endothelial growth factor is a key mitogen for malignant pleural mesothelioma cells, therefore targeting
Autor:
Catherine Dubos Arvis, Joo Hang Kim, Marcelo Garrido, Paul Baas, Margarita Majem, Gregory M. Lubiniecki, Mary J. Fidler, Marisa Dolled-Filhart, Gilberto de Castro, Enriqueta Felip, Yue Shentu, Julian R. Molina, Roy S. Herbst, Myung-Ju Ahn, Jose Luis Perez-Gracia, Dong Wan Kim, Edward B. Garon, Ji Youn Han, Ellie Im
Publikováno v:
LANCET
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Lancet, 387(10027), 1540-1550. Elsevier Limited
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Lancet, 387(10027), 1540-1550. Elsevier Limited
Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for progressive disease. We assessed the efficacy of pembrolizumab for patients with previously treated, PD-L1-p
Autor:
Vicki A. Morrison, Shmuel Shoham, Johan Maertens, John W. Baddley, Werner J. Heinz, Oliver A. Cornely, Dimitrios P. Kontoyiannis, Kieren A. Marr, Dong-Gun Lee, Thomas F. Patterson, Michael Giladi, Andrew J. Ullmann, Misun Lee, Mickael Aoun, Meinolf Karthaus, Galia Rahav, Dionysios Neofytos, Ilana Oren, Bernhardt Zeiher, Olivier Lortholary, Issam I Raad, Dominik Selleslag, Rochelle Maher, Eric J. Bow, Anne Schmitt-Hoffmann, George Richard Thompson, William W. Hope, Raoul Herbrecht
Publikováno v:
The Lancet. 387:760-769
Summary Background Isavuconazole is a novel triazole with broad-spectrum antifungal activity. The SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients with invasive mould disease. Methods This was a phase 3, doub